Back

Clinical Trial Evidence of Omega-3 Fatty Acids in ASCVD.

31 August 2020 (13:03 - 13:20)
Organised by:
Congress Presentation Part of: Clinical Update on Managing Hypertriglyceridaemia with Omega-3 Fatty Acid Icosapent Ethyl Cardiovascular Risk Assessment Open Access ESC Congress 2020

About the speaker

Photo
Professor Philippe Gabriel Steg

Hospital Bichat-Claude Bernard, Paris (France)

4 More presentations in this session

Presentation thumbnail
Welcome and Introductions, Program Overview.
Professor P. Steg (Paris, FR)
Video
Presentation thumbnail
Hypertriglyceridaemia as a Causal Factor and Target for Therapy.
Professor B. Nordestgaard (Copenhagen, DK)
Video
Presentation thumbnail
Practical Considerations on Using Omega-3 Fatty Acids to Prevent ASCVD.
Professor B. Nordestgaard (Copenhagen, DK)
Video
Presentation thumbnail
Live Q&A and Adjourn.
Professor P. Steg (Paris, FR) Professor B. Nordestgaard (Copenhagen, DK)
Video

Access the full session

Session thumbnail
Clinical Update on Managing Hypertriglyceridaemia with Omega-3 Fatty Acid Icosapent Ethyl
Video

The Event

Event poster

ESC Congress 2020

31 August 2020 13:03 CET
You may be interested in
thumbnail
Webinar
Risk assessment and lipid management in primary prevention
thumbnail
Webinar
Unmet needs in lipid management: treatment goals and how to achieve them
thumbnail
Webinar
Update on dyslipidaemia management: focus on risk estimation and lipoprotein(a)

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources